

571-273-8300

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/071,962	RECEIVED CENTRAL FAX CENTER JAN 22 2007
	Filing Date	Feb 8, 2002	
	First Named Inventor	Paul Ni	
	Art Unit	1647	
	Examiner Name	L. Spector	
	Attorney Docket Number	TNX98-03-01	
Total Number of Pages In This Submission		4	

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input checked="" type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Tanox, Inc.		
Signature			
Printed name	Cheryl A Liljestrand		
Date	January 22, 2007	Reg. No.	45,275

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Cheryl A Liljestrand	Date	January 22, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

JAN 22 2007

PATENT
ATTORNEY DOCKET NO.: TNX98-03-01
CUSTOMER NO: 26839

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:
Ni, Paul et al.

Serial No.: 10/071,962

Filed: February 8, 2002

For: G-CSF RECEPTOR AGONIST ANTIBODIES
AND SCREENING METHODS THEREFOR

Group Art Unit: 1647

Examiner: L. Spector

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Dear Sir:**RESPONSE TO NOTICE OF NON-COMPLIANT APPEAL BRIEF**

On December 22, 2006, the Office issued notification that the Appeal Brief filed on October 10, 2006 did not comply with the requirements of 37 CFR 41.37. This response is being filed within the one-month response period and therefore no fee should be due. However, should any fees be necessary, please charge our deposit account 20-0087.


Appellants have corrected the numbering of the claims. Claims 36-38 were incorrectly numbered as 34-36 due to an automatic function in MS Word, the substance of the claims was correct. The attached set of claims should be substituted for the claims filed with the original Appeal Brief.

Appellants submit that the attached set of claims complies with all of the requirements under 37 CFR 41.37.

Respectfully Submitted,

Dated: January 22, 2007.

BY:


Cheryl A. Liljestrand
Reg. No. 45,275
Tel.: (713) 578-4182**BEST AVAILABLE COPY**

RECEIVED
CENTRAL FAX CENTER

JAN 22 2007

Application No. 10/071,962
Appeal Brief
Customer Number 26839
Attorney Docket No.: TNX98-03-01
Page 8 of 11

VIII. Claims Appendix**Claims on Appeal:**

31. An agonist antibody, or a binding fragment thereof, that specifically binds to or interacts with the extracellular domain of human G-CSF receptor to stimulate cell proliferation and differentiation.
32. The agonist antibody, or binding fragment thereof, of claim 31, which dimerizes the receptor or activates phosphorylation of kinases associated with the receptor to stimulate cell proliferation and differentiation.
33. The agonist antibody or binding fragment of claim 31 or 32, which stimulates proliferation and differentiation of neutrophils or their progenitor cells.
36. The agonist antibody or binding fragment of claim 31 or 32, wherein the antibody interacts at an epitope between amino acid residues 1-603 (SEQ ID NO:27) of the G-CSF receptor.
37. The agonist antibody or binding fragment of claim 31 or 32, wherein said antibody is a monoclonal antibody.
38. The agonist antibody or binding fragment of claim 31 or 32, wherein the fragment is $F(ab')_2$.
40. A cell line that produces the agonist antibody or binding fragment of claim 31.
45. A composition comprising at least one agonist antibody according to claim 31 or 32, and a physiologically acceptable carrier, diluent, and/or excipient.
48. An agonist antibody, or binding fragment thereof, that specifically binds to or interacts with the extracellular domain of human G-CSF receptor wherein the

BEST AVAILABLE COPY

Application No. 10/071,962

Appeal Brief

Customer Number 26839

Attorney Docket No.: TNX98-03-01

Page 9 of 11

human G-CSF receptor used to generate said antibody is a native human G-CSF receptor or a mutant thereof comprising substitutions, insertions, or deletions.

49. The agonist antibody of claim 31, wherein the antibody comprises
SEQ ID NO: 15 to SEQ ID NO 20, or a functional variant of any one of SEQ ID
Nos 15 to 20.
50. The agonist antibody of claim 48, wherein the framework is human or
humanized.

BEST AVAILABLE COPY